TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Brief description of study

If you have been diagnosed with prostate cancer, that is found to be metastatic castration-resistant, which is a disease state characterized by resistance to standard androgen deprivation therapies (ADT) and if your cancer has one of a specific set of genetic mutations in DNA damage repair (homologous recombination deficiency( you may qualify to participate in this study.  The main goal of this phase III study is to evaluate the effectiveness of the drug rucaparib versus physician's choice of treatment to treat your type of cancer (mCRPC).  In addition, we would like to study blood samples to understand how much rucaparib is in your blood over a particular time course.


Clinical Study Identifier: s16-02260
ClinicalTrials.gov Identifier: NCTs16-02260


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.